Zobrazeno 71 - 80
of 627
pro vyhledávání: ''
Autor:
Bertram, Pitt, Marc A, Pfeffer, Susan F, Assmann, Robin, Boineau, Inder S, Anand, Brian, Claggett, Nadine, Clausell, Akshay S, Desai, Rafael, Diaz, Jerome L, Fleg, Ivan, Gordeev, Brian, Harty, John F, Heitner, Christopher T, Kenwood, Eldrin F, Lewis, Eileen, O'Meara, Jeffrey L, Probstfield, Tamaz, Shaburishvili, Sanjiv J, Shah, Scott D, Solomon, Nancy K, Sweitzer, Song, Yang, Sonja M, McKinlay, M, Yamani
Publikováno v:
New England Journal of Medicine. 370:1383-1392
Background Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and a preserved left v
Autor:
Florence Abravanel, Sophie Hillaire, Louis d’Alteroche, Vincent Mallet, Jacques Izopet, Lionel Rostaing, Audrey Coilly, Anne-Marie Roque-Afonso, Sébastien Dharancy, Maryvonne Hourmant, Michael Bismuth, Nassim Kamar, Anne Minello, Jérôme Dumortier, Lionel Couzi, Matthias Büchler, Pascal Lebray, Valérie Garrigue, Stanislas Pol, Simona Tripon, Sylvie Radenne
Publikováno v:
New England Journal of Medicine. 370:1111-1120
Background There is no established therapy for hepatitis E virus (HEV) infection. The aim of this retrospective, multicenter case series was to assess the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV vi
Autor:
Gregory T. Everson, Dennis Hernandez, K. Rajender Reddy, Dennis M. Grasela, Maribel Rodriguez-Torres, Paul J. Thuluvath, David R. Nelson, Min Gao, Federico Hinestrosa, William T. Symonds, Anna S. Lok, Eric Lawitz, David F. Gardiner, Claudio Pasquinelli, Fiona McPhee, Diane Sherman, Megan Wind-Rotolo, R. Hindes, Shu-Pang Huang, Timothy Eley, Tarek Hassanein, Ira M. Jacobson, Mark S. Sulkowski, Howard J. Schwartz
Publikováno v:
New England Journal of Medicine. 370:211-221
All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patie
Autor:
Tami Pilot-Matias, David R. Nelson, Mark S. Sulkowski, Wangang Xie, Paul Y. Kwo, George Liossis, Fred Poordad, Gregory T. Everson, Amit Khatri, Lois Larsen, Stefan Zeuzem, Graham R. Foster, Kris V. Kowdley, B. Bernstein, Eric Lawitz, Daniel E. Cohen, Thomas Podsadecki
Publikováno v:
New England Journal of Medicine. 370:222-232
An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HC
Autor:
Todd A. Conner, Robert F. Reilly, William C. Duckworth, Linda F. Fried, Peter A. McCullough, Stephen L. Seliger, Mary Brophy, Nicholas V. Emanuele, Paul M. Palevsky, Peter Guarino, Theresa Z. O'Connor, Suzanne Watnick, Jane H. Zhang, Stuart R. Warren, David J. Leehey, Peter Peduzzi
Publikováno v:
New England Journal of Medicine. 369:1892-1903
Background Combination therapy with angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provide
Autor:
Parker, C, Nilsson, S, Heinrich, D, Helle, Si, O'Sullivan, Jm, Fosså, Sd, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, Dc, Hoskin, P, Bottomley, D, James, Nd, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Coleman, R, Vogelzang, Nj, O'Bryan Tear CG, Staudacher, K, Garcia Vargas, J, Shan, M, Bruland, Øs, Sartor, O, Alsympca, Investigators, Aglietta, Massimo
Publikováno v:
NEW ENGLAND JOURNAL OF MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men wi
Autor:
Richard M, Bergenstal, David C, Klonoff, Satish K, Garg, Bruce W, Bode, Melissa, Meredith, Robert H, Slover, Andrew J, Ahmann, John B, Welsh, Scott W, Lee, Francine R, Kaufman, R, Weinstock
Publikováno v:
New England Journal of Medicine. 369:224-232
The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of hypoglycemia by interrupting insulin delivery at a preset sensor glucose value. We evaluated sensor-augmented insulin-pump therapy with and without th
Autor:
Stuart C. Gordon, David L. Wyles, Aasim Sheikh, Maribel Rodriguez-Torres, John McNally, Sarah Arterburn, Robert H. Hyland, M. Davis, Eric Lawitz, Tarek Hassanein, G. Mani Subramanian, Kris V. Kowdley, Zeid Kayali, Ira M. Jacobson, William T. Symonds, Diana M. Brainard, Deyuan Jiang, Michael Schultz, Alessandra Mangia, K. Rajender Reddy, L. Nyberg, Edward Gane, John G. McHutchison, Zobair M. Younossi
Publikováno v:
New England Journal of Medicine. 368:1878-1887
In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection.We conducted two phase 3 studies in previously untreated patients with
Autor:
Earl B. Britt, Bruce S. Levison, Zeneng Wang, Xiaoming Fu, W.H. Wilson Tang, Robert A. Koeth, Stanley L. Hazen, Yuping Wu
Publikováno v:
New England Journal of Medicine. 368:1575-1584
Recent studies in animals have shown a mechanistic link between intestinal microbial metabolism of the choline moiety in dietary phosphatidylcholine (lecithin) and coronary artery disease through the production of a proatherosclerotic metabolite, tri
Autor:
Catherine A.M. Stedman, M.M. Berrey, Evguenia S. Svarovskaia, William T. Symonds, Xiao Ding, Edward Gane, R. Hindes, Robert H. Hyland
Publikováno v:
New England Journal of Medicine. 368:34-44
The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and